
Prothena (PRTA) Stock Forecast & Price Target
Prothena (PRTA) Analyst Ratings
Bulls say
Prothena Corp PLC has a promising clinical pipeline focused on treating neurodegenerative and rare diseases, particularly through its antibody-based product candidates, which have shown a favorable reduction in amyloid levels in various dosing studies. The company has guided the potential to earn up to $105 million in aggregate milestones by 2026, primarily from partnerships with Novo Nordisk and Bristol-Myers Squibb, which underscores its strategic collaborations and revenue-generating potential. Despite some safety concerns related to elevated ARIA incidence in specific treatments, overall tolerability remains favorable, positioning Prothena Corp well for future growth in the biotechnology sector.
Bears say
Prothena Corp faces a negative outlook primarily due to ongoing net losses projected to continue until at least product approval and commercialization, necessitating additional capital raises that may dilute shareholder value. The uncertainties surrounding regulatory approvals increase risks for the company's pipeline of investigational therapeutics, which includes candidates targeting serious conditions like amyloidosis and neurodegenerative diseases. Furthermore, the recent findings regarding elevated ARIA levels with strong amyloid reduction in PRX012 highlight clinical risks that may hinder the successful development and commercialization of its product candidates.
This aggregate rating is based on analysts' research of Prothena and is not a guaranteed prediction by Public.com or investment advice.
Prothena (PRTA) Analyst Forecast & Price Prediction
Start investing in Prothena (PRTA)
Order type
Buy in
Order amount
Est. shares
0 shares